133 related articles for article (PubMed ID: 31581912)
21. Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199).
Phillips DC; Xiao Y; Lam LT; Litvinovich E; Roberts-Rapp L; Souers AJ; Leverson JD
Blood Cancer J; 2015 Nov; 5(11):e368. PubMed ID: 26565405
[TBL] [Abstract][Full Text] [Related]
22. High efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibition.
Bate-Eya LT; den Hartog IJ; van der Ploeg I; Schild L; Koster J; Santo EE; Westerhout EM; Versteeg R; Caron HN; Molenaar JJ; Dolman ME
Oncotarget; 2016 May; 7(19):27946-58. PubMed ID: 27056887
[TBL] [Abstract][Full Text] [Related]
23. Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL-1 and sensitizes high-risk Diffuse Large B-cell Lymphoma to BCL2 inhibition.
Dey J; Deckwerth TL; Kerwin WS; Casalini JR; Merrell AJ; Grenley MO; Burns C; Ditzler SH; Dixon CP; Beirne E; Gillespie KC; Kleinman EF; Klinghoffer RA
Sci Rep; 2017 Dec; 7(1):18007. PubMed ID: 29269870
[TBL] [Abstract][Full Text] [Related]
24. Targeting MCL1, Companies Aim to Unblock Apoptosis.
Cancer Discov; 2019 May; 9(5):572. PubMed ID: 30944116
[TBL] [Abstract][Full Text] [Related]
25. 3-Thiomorpholin-8-oxo-8H-acenaphtho [1,2-b] pyrrole-9-carbonitrile (S1) derivatives as pan-Bcl-2-inhibitors of Bcl-2, Bcl-xL and Mcl-1.
Song T; Li X; Chang X; Liang X; Zhao Y; Wu G; Xie S; Su P; Wu Z; Feng Y; Zhang Z
Bioorg Med Chem; 2013 Jan; 21(1):11-20. PubMed ID: 23206987
[TBL] [Abstract][Full Text] [Related]
26. Towards the next generation of dual Bcl-2/Bcl-xL inhibitors.
Varnes JG; Gero T; Huang S; Diebold RB; Ogoe C; Grover PT; Su M; Mukherjee P; Saeh JC; MacIntyre T; Repik G; Dillman K; Byth K; Russell DJ; Ioannidis S
Bioorg Med Chem Lett; 2014 Jul; 24(14):3026-33. PubMed ID: 24881567
[TBL] [Abstract][Full Text] [Related]
27. Norcantharidin enhances ABT-737-induced apoptosis in hepatocellular carcinoma cells by transcriptional repression of Mcl-1.
Zhang S; Li G; Ma X; Wang Y; Liu G; Feng L; Zhao Y; Zhang G; Wu Y; Ye X; Qin B; Lu J
Cell Signal; 2012 Sep; 24(9):1803-9. PubMed ID: 22609455
[TBL] [Abstract][Full Text] [Related]
28. Acylpyrogallols as inhibitors of antiapoptotic Bcl-2 proteins.
Tang G; Nikolovska-Coleska Z; Qiu S; Yang CY; Guo J; Wang S
J Med Chem; 2008 Feb; 51(4):717-20. PubMed ID: 18237106
[TBL] [Abstract][Full Text] [Related]
29. Potential mechanisms of resistance to venetoclax and strategies to circumvent it.
Tahir SK; Smith ML; Hessler P; Rapp LR; Idler KB; Park CH; Leverson JD; Lam LT
BMC Cancer; 2017 Jun; 17(1):399. PubMed ID: 28578655
[TBL] [Abstract][Full Text] [Related]
30. BCL-2: Long and winding path from discovery to therapeutic target.
Schenk RL; Strasser A; Dewson G
Biochem Biophys Res Commun; 2017 Jan; 482(3):459-469. PubMed ID: 28212732
[TBL] [Abstract][Full Text] [Related]
31. Design, synthesis, stereochemical determination, molecular docking study, in silico pre-ADMET prediction and anti-proliferative activities of indole-pyrimidine derivatives as Mcl-1 inhibitors.
Lamie PF; Philoppes JN
Bioorg Chem; 2021 Nov; 116():105335. PubMed ID: 34509795
[TBL] [Abstract][Full Text] [Related]
32. Discovery of potent and selective Bcl-2 inhibitors with acyl sulfonamide skeleton.
Wang B; Feng W; Wang J; Dong Y; Liu Y; Yao Y; Zhang J; Shi W; Liu L; Zhang H; He X; Chang X; Wang X; Xu H; Liu F; Feng J
Bioorg Med Chem; 2021 Oct; 47():116350. PubMed ID: 34536651
[TBL] [Abstract][Full Text] [Related]
33. Combined inhibition of RAC1 and Bcl-2/Bcl-xL synergistically induces glioblastoma cell death through down-regulation of the Usp9X/Mcl-1 axis.
Hlavac M; Dwucet A; Kast RE; Engelke J; Westhoff MA; Siegelin MD; Debatin KM; Wirtz CR; Halatsch ME; Karpel-Massler G
Cell Oncol (Dordr); 2019 Jun; 42(3):287-301. PubMed ID: 30859392
[TBL] [Abstract][Full Text] [Related]
34. Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1.
Teh TC; Nguyen NY; Moujalled DM; Segal D; Pomilio G; Rijal S; Jabbour A; Cummins K; Lackovic K; Blombery P; Thompson E; Ekert PG; Lessene G; Glaser SP; Huang DCS; Roberts AW; Guthridge MA; Wei AH
Leukemia; 2018 Feb; 32(2):303-312. PubMed ID: 28751770
[TBL] [Abstract][Full Text] [Related]
35. Targeting Bcl-2 for the treatment of multiple myeloma.
Touzeau C; Maciag P; Amiot M; Moreau P
Leukemia; 2018 Sep; 32(9):1899-1907. PubMed ID: 30076373
[TBL] [Abstract][Full Text] [Related]
36. Using CETSA assay and a mathematical model to reveal dual Bcl-2/Mcl-1 inhibition and on-target mechanism for ABT-199 and S1.
Guo Z; Song T; Xue Z; Liu P; Zhang M; Zhang X; Zhang Z
Eur J Pharm Sci; 2020 Jan; 142():105105. PubMed ID: 31669390
[TBL] [Abstract][Full Text] [Related]
37. Structure-based discovery of BM-957 as a potent small-molecule inhibitor of Bcl-2 and Bcl-xL capable of achieving complete tumor regression.
Chen J; Zhou H; Aguilar A; Liu L; Bai L; McEachern D; Yang CY; Meagher JL; Stuckey JA; Wang S
J Med Chem; 2012 Oct; 55(19):8502-14. PubMed ID: 23030453
[TBL] [Abstract][Full Text] [Related]
38. Discovery of small-molecule inhibitors of Bcl-2 through structure-based computer screening.
Enyedy IJ; Ling Y; Nacro K; Tomita Y; Wu X; Cao Y; Guo R; Li B; Zhu X; Huang Y; Long YQ; Roller PP; Yang D; Wang S
J Med Chem; 2001 Dec; 44(25):4313-24. PubMed ID: 11728179
[TBL] [Abstract][Full Text] [Related]
39. Functional disparities among BCL-2 members in tonsillar and leukemic B-cell subsets assessed by BH3-mimetic profiling.
Peperzak V; Slinger E; Ter Burg J; Eldering E
Cell Death Differ; 2017 Jan; 24(1):111-119. PubMed ID: 27689871
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of Mitochondrial Matrix Chaperones and Antiapoptotic Bcl-2 Family Proteins Empower Antitumor Therapeutic Responses.
Karpel-Massler G; Ishida CT; Bianchetti E; Shu C; Perez-Lorenzo R; Horst B; Banu M; Roth KA; Bruce JN; Canoll P; Altieri DC; Siegelin MD
Cancer Res; 2017 Jul; 77(13):3513-3526. PubMed ID: 28522750
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
